Results 91 to 100 of about 20,508 (222)

Available evidence and outcome of off-label use of rituximab in clinical practice [PDF]

open access: yes, 2013
Purpose: To analyze the therapeutic indications for off-label use of rituximab, the available evidence for its use, the outcomes, and the cost. Methods: This was a retrospective analysis of patients treated with rituximab for off-label indications from ...
A. Agustí   +34 more
core   +2 more sources

Rapid Recognition of Carfilzomib‐Induced Thrombotic Microangiopathy and Early Application of Eculizumab Successfully Rescued Two Relapsed Myeloma Patients

open access: yes
Chronic Diseases and Translational Medicine, Volume 12, Issue 1, Page 63-68, March 2026.
Zi Wang   +6 more
wiley   +1 more source

Atypical hemolytic uremic syndrome [PDF]

open access: yes, 2011
Hemolytic uremic syndrome (HUS) is defined by the triad of mechanical hemolytic anemia, thrombocytopenia and renal impairment. Atypical HUS (aHUS) defines non Shiga-toxin-HUS and even if some authors include secondary aHUS due to Streptococcus pneumoniae
Chantal Loirat   +1 more
core   +2 more sources

Causal relationship between immune cells and idiopathic thrombocytopenic purpura: A bidirectional Mendelian randomization study

open access: yes
Rheumatology &Autoimmunity, Volume 6, Issue 1, Page 63-65, March 2026.
Heyi Zhang   +9 more
wiley   +1 more source

Pulmonary Tuberculosis Complicated by Thrombotic Thrombocytopenic Purpura: A Case Report and Literature Review

open access: yesInfection and Drug Resistance
Jun Zheng,1 Xiaohong Pan,2 Yiyun Jiang3 1Department of Rehabilitation, Nanxing Health Service Center, Shangcheng, Hangzhou, Zhejiang, 310000, People’s Republic of China; 2Tuberculosis Care Unit, Hospital of Integrated Traditional Chinese and Western ...
Zheng J, Pan X, Jiang Y
doaj  

Idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report

open access: yesJournal of Medical Case Reports, 2011
Introduction Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is a life-threatening condition with various etiopathogeneses. Without therapy approximately 90% of all patients die from the disease. Case presentation We report the case of a 17-
Patschan Daniel   +7 more
doaj   +1 more source

The effect of single nucleotide polymorphisms and mutations on congenital thrombotic thrombocytopenic purpura phenotype [PDF]

open access: yes, 2017
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disease with a reported incidence of 6 cases per million per year in the UK. It is characterised by episodes of microangiopathic haemolytic anaemia and thrombocytopenia, with the ...
Tate, H., Tate, H.
core  

Thrombotic Thrombocytopenic Purpura [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1959
J, LORBER, J L, EMERY
openaire   +2 more sources

Effect of blood groups on acquired and congenital thrombotic thrombocytopenic purpura and clinical correlation: Multi-center Turkish cohort study

open access: yesHematology, Transfusion and Cell Therapy
Background: Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic hemolytic anemia associated with ADAMTS-13 deficiency, a cleaving protease of von Willebrand factor (vWF).
Cevat İlteriş Kıkılı   +4 more
doaj   +1 more source

A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13 [PDF]

open access: yes, 2017
In this case report, we describe for the first time a patient with thrombotic thrombocytopaenic purpura (TTP) accompanying highly active systemic lupus erythematosus (SLE) that was associated with non-neutralizing antibodies against the plasma ...
Ferrari, Silvia   +4 more
core  

Home - About - Disclaimer - Privacy